Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
3
users have commented on this narrative
45
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Centerspace
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Midwest And Salt Lake City Markets Will Realize Rental Potential
Key Takeaways Persistent rental demand and demographic trends in key markets drive high occupancy, rent growth, and tenant retention for stable long-term revenue. Strategic recycling into higher-growth properties and disciplined balance sheet management enhance portfolio quality, margins, and position for further growth.
View narrative
US$69.05
FV
19.9% undervalued
intrinsic discount
2.88%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
TechTarget
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
B2B Digital Transformation And AI Will Expand Market Reach
Key Takeaways Proprietary data assets and AI-driven solutions position TechTarget for strong customer retention, pricing power, and differentiation in a rapidly evolving B2B digital landscape. Innovation in platforms, ecosystem integrations, and international focus drive greater client engagement, operational efficiency, and long-term revenue growth potential.
View narrative
US$12.33
FV
50.5% undervalued
intrinsic discount
19.15%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
3 days ago
author updated this narrative
Xencor
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
IBD Biologics And TL1A Programs Will Forge New Paths
Key Takeaways Differentiated drug design and flexible development platform position Xencor for increased patient adoption, operational efficiency, and attractive long-term profitability. Strong clinical strategy and alignment with healthcare trends support sustained market expansion and robust future revenue growth.
View narrative
US$26.90
FV
71.5% undervalued
intrinsic discount
12.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
3 days ago
author updated this narrative
E Ink Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 13 Analysts
Digital Shelf Labels And Eco-Friendly Signage Will Expand Global Markets
Key Takeaways Robust adoption of ESL and digital signage, coupled with sustainability focus, is driving recurring revenue growth and supporting premium pricing with stable margins. Expanding partnerships and new production capacity enable broader market reach, operational leverage, and stronger long-term earnings stability.
View narrative
NT$322.38
FV
21.4% undervalued
intrinsic discount
18.95%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
Updated
narrative
Arrowhead Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
Key Takeaways Advancing RNAi therapy pipeline and global partnerships boost Arrowhead's growth prospects, competitive position, and access to emerging healthcare markets. Strategic collaborations and favorable regulatory trends support revenue stability, strong margins, and opportunities for long-term earnings and expansion.
View narrative
US$43.79
FV
53.2% undervalued
intrinsic discount
-11.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
3 days ago
author updated this narrative
Tempus AI
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Expanding Genomic Testing And AI Will Build Lasting Healthcare Value
Key Takeaways Strong growth in testing volumes and biopharma partnerships positions Tempus AI for durable revenue gains, supported by differentiated technology and a growing data advantage. Expanding clinical-genomic offerings and disciplined cost management drive improving profitability, while rising AI adoption and regulatory clarity provide long-term growth opportunities.
View narrative
US$69.50
FV
6.2% overvalued
intrinsic discount
29.79%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
98
users have followed this narrative
3 days ago
author updated this narrative
Lumen Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
AI-Driven Networks And Cloud Integrations Will Transform Infrastructure
Key Takeaways Refocusing on enterprise and digital segments, backed by AI-driven infrastructure and platform contracts, positions the company for margin expansion and sustained long-term earnings growth. Financial restructuring, asset sales, and targeted partnerships bolster network modernization, capitalize on data growth, and support commercial reach in high-demand connectivity solutions.
View narrative
US$4.83
FV
8.2% undervalued
intrinsic discount
-3.94%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
48
users have followed this narrative
3 days ago
author updated this narrative
BridgeBio Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 21 Analysts
Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons
Key Takeaways Strong growth in a key drug and diversified late-stage pipeline position BridgeBio for sustained revenue momentum, market leadership, and improved profit margins. Efficient commercialization strategy and ample cash reserves support future product launches without requiring immediate equity dilution, strengthening operational leverage.
View narrative
US$62.43
FV
17.8% undervalued
intrinsic discount
92.20%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
3 days ago
author updated this narrative
Awfis Space Solutions
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Urban Expansion And Flexible Work Models Will Transform Markets
Key Takeaways Expansion into smaller cities and premium workspaces increases addressable market, tenant retention, and margin potential. Diversified services and asset-light models enhance profitability, operating leverage, and long-term earnings visibility.
View narrative
₹862.20
FV
34.9% undervalued
intrinsic discount
23.12%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies